Exonhit Enters Into Research Agreement With Pfizer to Identify Alzheimer’s Disease Biomarkers
Exonhit announced that it has entered into a research agreement with Pfizer Inc. for the identification of new Alzheimer’s disease (AD) biomarkers using Exonhit’s Genome-Wide SpliceArray™ (GWSA) platform.
As part of the agreement, the two companies will jointly conduct a pilot study using Exonhit’s GWSA platform to gain insight on AD molecular markers associated with clinical parameters. More specifically, the purpose of the research work is to seek to identify progression and other biomarkers that could segregate healthy elderly controls, patients with mild cognitive impairment (MCI) and patients with AD. Test samples for the study will be provided by Pfizer from a number of subjects in each of these three groups over a period of time.
Financial details were not disclosed.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.